TCR-NK: A novel cell therapy transforming cancer treatment
Are TCR-NK treatments the next big thing in cell therapies for cancer patients?As biotechs and pharma companies continue to innovate to address patient needs in oncology, T-cell receptor therapies, or TCR-Ts, are attracting significant interest and investment. There are already some promising results for TCR-Ts tackling solid tumors – but one Norwegian biotech is taking a slightly different track.This week, we sit down with Namir Hassan, CEO of Zelluna, a company with a mission to eliminate solid cancers by pioneering the development of T cell receptor guided natural killer, or TCR-NK, cell therapies.01:45 Introducing Namir Hassan03:37 Working at Immunocore04:40 Lessons learned06:56 Joining Zelluna as CSO08:44 Becoming Zelluna CEO10:20 Taking a biotech company public12:54 TCR-T and TCR-NK therapies15:30 Targets for TCR-NK therapies16:38 Comparing TCR-NK to alternatives20:16 Early success21:58 An off-the-shelf-solution for cancer patients24:16 Manufacturing and scaling25:13 Partnering with top pharma, accelerating innovation27:05 Milestones ahead for Zelluna28:52 The landscape of TCR therapies in oncology31:38 A final wordInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Future of cancer treatment: what will therapy look like in 2034?Trends in cancer therapeutics to look forward to in 2025Oncology R&D trends and breakthrough innovations
--------
34:00
AI in biotech today, and how it will impact the industry tomorrow
AI is driving innovation across industries, including biotech, but where is its influence felt most and what opportunities for future impact are emerging?David del Bourgo is the co-founder and CEO of WhiteLab Genomics, an innovative biotech that is leveraging the power of AI to accelerate drug discovery and development from its Paris, Boston, and Montreal bases. In this episode he explains how WhiteLab uses AI technologies to identify targets and engineer vectors, but also offers a wider view of how and where AI is impacting the biotech industry generally.01:04 Introducing David del Bourgo04:06 The WhiteLab Genomics mission10:54 AI in biotech: what’s working now14:07 AI in biotech: emerging applications15:58 Regulating AI in biotech and in general17:21 Acceleration and cost savings thanks to AI19:09 AI’s impact on accuracy and precision21:07 The trade-off with AI in biotech22:38 Why top pharma companies aren’t building their own AI tools24:43 AI and biomanufacturing26:58 AI in biotech and pharma operations28:40 The next impacts of AI in biotech30:38 Accelerating regulatory review with AI32:24 Emerging AI techniques in biotech33:59 The pace of AI innovation35:21 The next challenge for AI in biotech36:10 A word for the AI skeptics Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 12 AI drug discovery companies you should know aboutThe AI boom in cancer: Game-changer or just hype?Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration
--------
39:40
How nanobodies will revolutionize immunotherapy
From llamas and camels to humans worldwide. Nanobodies are enjoying success in the clinic and experts are hailing these camelid-derived biologics as one of the next big things in immunotherapy.Kristian Reich is co-founder and CSO of MoonLake Immunotherapeutics. After a long and distinguished career as a clinician and researcher, Kristian helped to launch MoonLake in 2021 and quickly helped move their lead candidate to the clinic. Now, on the verge of Phase III trials, he joins 'Beyond Biotech' to talk nanobodies, innovation, serendipitous science, and the power that comes from never stopping to dream.01:04 Meet Kristian Reich05:26 Excited by the science of nanobodies07:13 MoonLake’s mission13:12 Milestones at MoonLake15:24 Introduction to nanobodies17:55 Serendipitous science19:46 How nanobodies work23:18 Global prevelance of immune conditions24:31 The impact on patients27:09 Nanobodies in the clinic31:19 Manufacturing challenges, regulatory challenges34:04 Working with top pharma35:55 The future of nanobodies37:42 The future of MoonLake39:10 Don’t stop dreamingInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter
--------
41:13
Meeting the global demand for cell therapies: scaling with smart manufacturing
Cell therapies are at the cutting edge of personalized medicine but as demand for these therapies grows, how will the industry scale manufacturing to meet patient needs?Fabian Gerlinghaus is co-founder and CEO of Cellares. He and his team have developed the Cell Shuttle, an advanced cell manufacturing technology that is already demonstrating the potential to 10x cell yields while halving costs for pharmaceuticals companies and innovators. Is this the future for smart cell manufacturing?0:52 A starting point in aeronautical engineering2:43 First steps into biotech5:25 Co-founding Cellares6:30 The problem that Cellares addresses11:02 Best practice bio manufacturing17:14 Differentiation in automation18:15 What does success look like for Cellares19:38 Smart factories21:58 Inside the Cellares smart factory26:34 Manufacturing CAR-T and stem cell therapies27:54 Mass production vs personalized medicine31:39 Global ambitions and regional regulators35:07 Positioning Cellares in the marketInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter
--------
39:38
Treating spinal cord injuries with stem cells
Spinal cord injuries impact millions of people worldwide and, unlike many chronic injuries, they usually arrive with no forewarning, impacting the young and old alike.Brian Culley is CEO of Lineage Cell Therapeutics and his company is now in the clinic with a stem cell therapy for spinal cord injuries. Learn why stem cells could be promising for these devastating injuries and how Brian and his team plan to overcome the challenges of manufacturing at scale and succeeding in a highly regulated space.00:57 Meet Brian Culley02:15 Lineage Cell Therapeutics and its mission04:56 Spinal cord injuries06:40 Costs beyond the Individual08:15 Current treatment options10:48 The place for stem cell therapies12:57 Lineage in the clinic16:27 The DOSED program18:37 The advantages of DOSED20:29 Timelines for results21:35 Scaling manufacturing24:28 Partnering with pharma on stem cell therapies26:38 Other applications for stem cell therapies28:49 Mainstreaming stem cell therapies30:52 Challenges ahead32:43 The future for Lineage Cell TherapeuticsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Polska